Episode Details

A groundbreaking genomic test is revolutionizing breast cancer treatment by helping thousands of women avoid chemotherapy—without sacrificing outcomes. By analyzing 50 genes in tumor tissue, the test predicts recurrence risk, revealing that many patients with low scores can safely rely on hormone therapy alone. In a massive international trial called Optima, over 4,000 patients showed nearly identical survival rates whether they received chemo or not. This precision approach slashes the physical and emotional toll of chemo—including infertility and cognitive issues—while paving the way for smarter, more personalized care. Expected to reshape global cancer guidelines, this breakthrough offers hope for millions, especially those with the most common hormone-positive breast cancer.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/d1e0529633894a94